Intrexon (XON) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its stake in shares of Intrexon (NYSE:XON) by 2.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 498,708 shares of the biotechnology company’s stock after acquiring an additional 12,847 shares during the quarter. Geode Capital Management LLC’s holdings in Intrexon were worth $5,744,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its stake in Intrexon by 1.4% during the third quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock worth $4,512,000 after buying an additional 3,234 shares during the period. SG Americas Securities LLC boosted its stake in Intrexon by 85.5% during the fourth quarter. SG Americas Securities LLC now owns 13,560 shares of the biotechnology company’s stock worth $156,000 after buying an additional 6,251 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in Intrexon during the third quarter worth about $121,000. Swiss National Bank boosted its stake in Intrexon by 10.0% during the fourth quarter. Swiss National Bank now owns 107,500 shares of the biotechnology company’s stock worth $1,238,000 after buying an additional 9,800 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in Intrexon by 31.1% during the fourth quarter. UBS Asset Management Americas Inc. now owns 46,839 shares of the biotechnology company’s stock worth $540,000 after buying an additional 11,104 shares during the period. 75.95% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

NYSE XON opened at $18.86 on Tuesday. The company has a quick ratio of 1.67, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Intrexon has a one year low of $10.26 and a one year high of $26.99. The company has a market capitalization of $2,532.28, a PE ratio of -20.50 and a beta of 1.11.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.08. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business had revenue of $77.03 million during the quarter, compared to analyst estimates of $48.16 million. During the same quarter last year, the firm posted ($0.37) earnings per share. The business’s revenue for the quarter was up 67.5% compared to the same quarter last year. equities research analysts anticipate that Intrexon will post -0.92 earnings per share for the current year.

In other Intrexon news, CEO Randal J. Kirk acquired 1,000,000 shares of the stock in a transaction dated Friday, January 19th. The stock was acquired at an average price of $12.50 per share, with a total value of $12,500,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 56.30% of the company’s stock.

XON has been the subject of several research analyst reports. ValuEngine lowered shares of Intrexon from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. Northland Securities reaffirmed a “buy” rating and set a $17.00 target price on shares of Intrexon in a research note on Friday, March 2nd. Bank of America lowered their target price on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, March 2nd. Finally, JPMorgan Chase reaffirmed a “neutral” rating and set a $18.00 target price (down previously from $22.00) on shares of Intrexon in a research note on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $34.67.

TRADEMARK VIOLATION WARNING: “Intrexon (XON) Shares Bought by Geode Capital Management LLC” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/04/17/intrexon-xon-shares-bought-by-geode-capital-management-llc.html.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply